• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abiomed CEO Minogue reaps $3.2 million from stock sales

Abiomed CEO Minogue reaps $3.2 million from stock sales

April 21, 2011 By MassDevice staff

ABMD logo

Abiomed Inc. (NSDQ:ABMD) CEO Michael Minogue rode the company’s hot stock performance this year to a $3.2 million payout, taking advantage of stock options in trades executed this month.

The Danvers, Mass.-based company’s shares have risen 73 percent since the close of 2010, hitting $16.63 yesterday, largely on the strength of its Impella heart pump. In a series of trades from late February to the end of March, Minogue sold more than 40,000 shares at an average price of $14.59, grossing about $583,000, according to filings with the federal Securities & Exchange Commission.

Another series of trades began April 4, when Minogue was able to acquire options at $9.05 per share. He bought 400,000 shares at that price and sold them at an average of $15.67, for a net profit of more than $2.6 million.

Read more of MassDevice.com’s coverage of Abiomed

Abiomed vastly outperformed both the S&P 500 and the Dow Jones IHI index of medical device stocks in the first quarter. The S&P 500 Index gained 5.4 percent during the period; the Dow IHI was up 9.1 percent during that span. ABMD stock averaged $12.32 during the quarter and closed the three months ended March 31 at $14.53.

The first-quarter spike (which corresponds to Abiomed’s fiscal 2011 fourth quarter) highlights the company’s steady advances since it won 510(k) clearance for the Impella 5.0 and LD pumps nearly two years ago. Back then Abiomed shares were trading at about $5.50; since then it’s reported steadily increasing sales and cut its net losses considerably. The company rang Wall Street’s bell — literally — with its third-quarter results, reporting that sales jumped nearly 23 percent during the three months ended Dec. 31., to $27.2 million. That helped it pare losses to just $802,000, or 2 cents per share. Abiomed posted losses of $4.6 million, or 12 cents per share, on sales of $22.8 million during Q3 2010.

That performance itself sent shares up about 25 percent that day, which ended with Minogue ringing the NASDAQ exchange’s closing bell.

Filed Under: News Well, Wall Street Beat Tagged With: Abiomed, Executive Compensation, Personnel Moves

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy